Ketorolac: Difference between revisions
(Text replacement - "HA" to "headache") |
Elcatracho (talk | contribs) (→Common) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
*Dosage Forms: 15mg/mL, 30mg/mL injection | *Dosage Forms: 15mg/mL, 30mg/mL injection | ||
*Common Trade Names: Toradol | *Common Trade Names: Toradol | ||
''Although standard packaging provides 30mg doses current research demonstrates that the analgesic ceiling for ketorolac appears to be 10 mg if given intravenously''<ref> Motov S et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. Ann Emerg Med 2016. PMID: 27993418</ref> | |||
==Adult Dosing== | ==Adult Dosing== | ||
*Acute pain: | *Acute pain: | ||
**IM: | **IM: 15mg x 1 or 15mg q6h | ||
**IV: | **IV: 15mg x 1, then 15mg q6h | ||
**Black box warning against treatment for > 5 days | **Black box warning against treatment for > 5 days | ||
| Line 32: | Line 33: | ||
*Bleeding, MI, CVA, GI bleed/perforation, Hyperkalemia | *Bleeding, MI, CVA, GI bleed/perforation, Hyperkalemia | ||
===Common=== | ===Common=== | ||
* | *Dyspepsia, nausea, headache | ||
==Pharmacology== | ==Pharmacology== | ||
| Line 44: | Line 45: | ||
==See Also== | ==See Also== | ||
*[[NSAID toxicity]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 22:50, 7 March 2021
General
- Type: NSAID
- Dosage Forms: 15mg/mL, 30mg/mL injection
- Common Trade Names: Toradol
Although standard packaging provides 30mg doses current research demonstrates that the analgesic ceiling for ketorolac appears to be 10 mg if given intravenously[1]
Adult Dosing
- Acute pain:
- IM: 15mg x 1 or 15mg q6h
- IV: 15mg x 1, then 15mg q6h
- Black box warning against treatment for > 5 days
Pediatric Dosing
- N/A
Special Populations
- Pregnancy Rating: C
- Lactation: Enters breast milk, use caution
- Elderly (> 65 yo): Decrease dose by 50%
- Renal Dosing
- Mild-Moderate impairment: Decrease dose by 50%
- Severe impairment or HD: Contraindicated
- Hepatic Dosing: No dose change, but may increase LFTs
Contraindications
- Allergy to class/drug
- Active or prior PUD, recent GI bleed
- Severe renal disease or HD
- Bleeding diathesis
Adverse Reactions
Serious
- Bleeding, MI, CVA, GI bleed/perforation, Hyperkalemia
Common
- Dyspepsia, nausea, headache
Pharmacology
- Onset: 20-30 minutes
- Peak: 2-3 hours
- Duration: 4-6 hours
- Half-life: 2-6 hours, up to 19 hours in renal disease
- Metabolism: Hepatic
- Excretion: Renal
- Mechanism of Action: NSAID, Reversible COX-1/2 inhibitor
See Also
References
- ↑ Motov S et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. Ann Emerg Med 2016. PMID: 27993418